Loading patent…
AssigneeExiris S.R.L.
InventorsPaola GALLINARI, Chantal PAOLINI, Gessica FILOCAMO, Mirko BRUNETTI, Armin LAHM, Hans-Friedrich GRUNERT, John THOMPSON, Lucia RICCI-VITIANI, Mauro BIFFONI
Estimating the term…
The present disclosure relates to monoclonal antibodies anti-FGFR4 and their use as medicaments and diagnostic agents. In particular, it relates to an antibody which specifically binds to the acid box domain of FGFR4 and to specific portions thereof. Nucleic acids coding for said antibody, vectors and host cells for their expression and production, antibody-drug conjugates and pharmaceutical compositions comprising said antibody are also within the scope of the present disclosure. The present disclosure also relates to antibodies anti-FGFR4 for use for detecting, killing, affecting or inhibiting development and/or differentiation of colon cancer stem cells.
A monoclonal antibody, or antigen-binding fragment thereof, that recognizes an epitope within the acid box domain of tyrosine kinase fibroblast growth factor receptor 4 (FGFR4), wherein the epitope is comprised between amino acids 119 to 156 of human FGFR4, wherein the monoclonal antibody, or antigen-binding fragment thereof, inhibits fibroblast growth factor 19 (FGF 19) binding to FGFR4.
12-13. (canceled)
21-22. (canceled)
(canceled)
Dependencies are inferred from the claim text.